Back to News
Market Impact: 0.15
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
Source: Business Wire
Healthcare & Biotech
Bristol Myers Squibb announced that it presented Phase 1 BREAKFREE-2 study results for zolacabtagene autoleucel (BMS-986353) in patients. The article excerpt provides no study outcomes, numerical results, or safety details to assess the clinical findings.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
BMY0.30
More News
- Next week brings major risks for the stock market, just as the AI trade keeps faltering
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal